In pancreatic cancer, the glypican-1 (GPC1)+ endosomes were reported as a diagnostic biomarker to distinguish healthy subjects and patients with a benign pancreatic disease from patients with early- and late-stage pancreatic cancer, with absolute specificity and sensitivity. This evidence concerns the gene GPC1 and familial pancreatic carcinoma.